Viemed Healthcare (VMD) AI Stock Analysis

• Market Cap: $254.82M
• Dividend Yield: N/A
• Average Volume (3M): 161.11K
• Price to Earnings (P/E): 19.4
• Beta (1Y): 1.06
• Revenue Growth: 17.11%
• EPS Growth: 45.34%
• Country: US
• Employees: 1,222
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): 0.08
• Shares Outstanding: 38,785,760
• 10 Day Avg. Volume: 130,736
• 30 Day Avg. Volume: 161,110
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 1.07
• Enterprise Value/Revenue: 1.13
• Enterprise Value/Gross Profit: 1.95
• Enterprise Value/Ebitda: 5.75
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 71 Outperform
• Price Target: $7.50 ▲(9.49% Upside)

Viemed Healthcare's overall stock score is driven by strong earnings call performance and solid financial stability. The company's strategic growth initiatives and raised guidance are significant positives. However, liquidity concerns due to negative free cash flow and moderate valuation metrics slightly temper the outlook.

Viemed Healthcare Business Overview & Revenue Model

Company Description

Viemed Healthcare (VMD) is a leading provider of home-based healthcare solutions, specializing in the management of patients with chronic respiratory diseases. The company operates primarily in the healthcare sector, offering products and services such as ventilators, oxygen therapy devices, and related clinical support. Viemed is committed to improving patient outcomes and quality of life through innovative healthcare delivery models and personalized care plans.

How the Company Makes Money

Viemed Healthcare generates revenue primarily through the leasing of medical equipment and the provision of respiratory therapy services. The company's key revenue streams include rental income from ventilators and oxygen devices, reimbursement from government and private insurance for therapy services, and sales of consumable supplies. Additionally, Viemed has established partnerships with healthcare providers and payers, which enhance its service offerings and facilitate access to a broader patient base, contributing significantly to its earnings.

Viemed Healthcare Financial Statement Overview

Summary

Viemed Healthcare demonstrates strong revenue growth and operational efficiency with healthy profit margins. The balance sheet is stable with low leverage and solid equity. Cash flow from operations is strong, though negative free cash flow signals caution in capital spending. Overall, the company is financially sound but could focus on improving net profitability and managing capital expenditures.

Income Statement

Viemed Healthcare has demonstrated solid revenue growth with a consistent upward trajectory from $117.06M in 2021 to $232.79M TTM. The gross profit margin is strong at 58.56% TTM, and the net profit margin has improved to 5.28% TTM. The EBIT and EBITDA margins are also healthy, indicating efficient operations. However, the net profit margin is relatively modest, suggesting room for profitability enhancement.

Balance Sheet

The company maintains a solid equity position with an equity ratio of 104.49% TTM, reflecting strong asset financing through equity. The debt-to-equity ratio is favorable at 0.05 TTM, indicating low leverage risk. Return on equity is moderate at 9.12% TTM. While the balance sheet shows stability, the moderate ROE suggests potential for better asset utilization to boost shareholder returns.

Cash Flow

Operating cash flow is robust at $40.77M TTM, but free cash flow has turned negative to -$6.48M TTM, largely due to increased capital expenditures. The operating cash flow to net income ratio is strong at 3.32 TTM, indicating effective cash conversion. The negative free cash flow suggests a need for careful capital management to ensure sustainability.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	240.88M	224.26M	183.01M	138.83M	117.06M	131.31M
Gross Profit	140.17M	133.20M	112.78M	84.68M	73.41M	80.11M
EBITDA	47.39M	42.31M	36.71M	24.03M	21.84M	30.54M
Net Income	13.98M	11.27M	10.24M	6.22M	9.13M	31.53M
Balance Sheet
Total Assets	184.60M	177.07M	154.90M	117.04M	117.96M	112.56M
Cash, Cash Equivalents and Short-Term Investments	20.02M	17.54M	12.84M	16.91M	28.41M	30.98M
Total Debt	6.89M	6.87M	10.32M	694.00K	6.52M	11.13M
Total Liabilities	42.98M	43.77M	41.00M	19.95M	23.14M	30.87M
Stockholders Equity	139.73M	131.39M	113.89M	97.09M	94.82M	81.69M
Cash Flow
Free Cash Flow	-3.60M	1.32M	19.12M	4.85M	2.75M	22.07M
Operating Cash Flow	42.84M	39.09M	45.21M	27.75M	22.49M	35.11M
Investing Cash Flow	-24.42M	-30.70M	-52.11M	-23.98M	-19.75M	-8.41M
Financing Cash Flow	-7.21M	-3.69M	2.83M	-15.27M	-5.32M	-9.07M

Viemed Healthcare Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 6.85
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VMD, the sentiment is Negative. The current price of 6.85 is above the 20-day moving average (MA) of 6.78, above the 50-day MA of 6.82, and below the 200-day MA of 7.04, indicating a bearish trend. The MACD of -0.07 indicates Positive momentum. The RSI at 42.47 is Neutral, neither overbought nor oversold. The STOCH value of 15.67 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for VMD.

Viemed Healthcare Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TCMD	―	$351.55M	25.33	7.64%	―	6.15%	-54.24%
VMD	―	$254.82M	19.39	10.79%	―	17.11%	45.34%
INGN	―	$222.00M	―	-13.46%	―	5.15%	73.29%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BVS	―	$559.74M	―	-0.10%	―	5.08%	99.38%
OM	―	$230.86M	―	-87.65%	―	2.47%	56.93%
SENS	―	$287.18M	―	-102.61%	―	5.94%	25.18%

Viemed Healthcare Corporate Events

Viemed Healthcare Completes Share Repurchase Program

On September 23, 2025, Viemed Healthcare announced the completion of its share repurchase program, having repurchased 1,976,441 common shares for approximately $13.2 million. This move underscores Viemed’s confidence in its long-term prospects and commitment to enhancing shareholder value, supported by a strong balance sheet and increasing free cash flow.

The most recent analyst rating on (VMD) stock is a Buy with a $7.50 price target. To see the full list of analyst forecasts on Viemed Healthcare stock, see the VMD Stock Forecast page.

Viemed Healthcare’s Earnings Call Highlights Robust Growth

Viemed Healthcare’s recent earnings call painted a picture of robust growth and strategic advancement, with the company showcasing significant achievements in its core operations. The sentiment was overwhelmingly positive, driven by strong performances in key areas such as ventilation and sleep therapy, alongside strategic acquisitions that have bolstered the company’s future outlook. Despite minor setbacks in the staffing sector and a slight dip in gross margins, Viemed’s overall trajectory remains promising, underscoring its solid positioning for continued success.

Viemed Healthcare Reports Strong Q2 2025 Growth

Viemed Healthcare, Inc. is a U.S.-based in-home clinical care provider specializing in post-acute respiratory healthcare equipment and services, including non-invasive ventilators and sleep therapy. The company focuses on delivering efficient in-home treatment through high-touch and high-tech services.

Viemed Healthcare Achieves Record Q2 2025 Revenues and Expands Guidance

Viemed Healthcare reported record net revenues of $63.1 million for the second quarter of 2025, marking a 14.7% increase from the previous year. The company’s net income rose by 115.1% to $3.2 million, and adjusted EBITDA increased by 11.5%. The acquisition of Lehan’s Medical Equipment has allowed Viemed to raise its full-year revenue and adjusted EBITDA guidance, reflecting the company’s strategic growth and strong operational performance. The company also repurchased shares, increased its patient count, and maintained a strong cash position, demonstrating robust financial health and commitment to shareholder value.

The most recent analyst rating on (VMD) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Viemed Healthcare stock, see the VMD Stock Forecast page.